secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zentalis Pharmaceuticals, Inc. (ZNTL)
CIK:        0001725160
Form:       8-K
Filed at:   2026-06-18T20:03:10+00:00
Accession:  0001725160-26-000052
Event type: other
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Zentalis shareholders elect two Class III directors, ratify auditor, approve say-on-pay at 2026 annual meeting
--------------------------------------------------------------------------------

- David Johnson and Jan Skvarka elected as Class III directors with 20.7M and 23.5M votes for, respectively.
- Ratification of Ernst & Young as auditor for FY2026 passed with 49.3M votes for (99.7% of votes cast).
- Advisory say-on-pay proposal approved with 21.9M for vs 10.9M against, excluding broker non-votes.
- Approximately 69.5% of outstanding shares (49.5M) were represented at the meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1725160/000172516026000052/0001725160-26-000052-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1725160/000172516026000052/zntl-20260616.htm
  HTML page:      https://secwatch.observer/filing/0001725160-26-000052

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer